121 related articles for article (PubMed ID: 34973279)
21. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu YP; Wen YH; Tang J; Wei Y; You R; Zhu XL; Li J; Chen L; Ling L; Zhang N; Zou X; Hua YJ; Chen YM; Chen L; Lu LX; Chen MY; Wen WP
Lancet Oncol; 2021 Mar; 22(3):381-390. PubMed ID: 33600761
[TBL] [Abstract][Full Text] [Related]
22. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis.
Du T; Xiao J; Qiu Z; Wu K
PLoS One; 2019; 14(7):e0219611. PubMed ID: 31291379
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone.
Su SF; Han F; Zhao C; Chen CY; Xiao WW; Li JX; Lu TX
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):327-33. PubMed ID: 21035959
[TBL] [Abstract][Full Text] [Related]
24. A Prospective Study on Defining the Indications of Prophylactic Level IB Radiotherapy in Nasopharyngeal Carcinoma Based on a Risk Score Model.
Zhang X; Yuan JJ; Ding JW; Zhang SH; Zhang ZL; Hu RH; Gong D; Hu JL; Tu ZW; Zeng L
Oncol Res Treat; 2022; 45(9):471-479. PubMed ID: 35705024
[TBL] [Abstract][Full Text] [Related]
25. A knowledge-based intensity-modulated radiation therapy treatment planning technique for locally advanced nasopharyngeal carcinoma radiotherapy.
Bai P; Weng X; Quan K; Chen J; Dai Y; Xu Y; Lin F; Zhong J; Wu T; Chen C
Radiat Oncol; 2020 Aug; 15(1):188. PubMed ID: 32746873
[TBL] [Abstract][Full Text] [Related]
26. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
[TBL] [Abstract][Full Text] [Related]
27. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.
Peng G; Wang T; Yang KY; Zhang S; Zhang T; Li Q; Han J; Wu G
Radiother Oncol; 2012 Sep; 104(3):286-93. PubMed ID: 22995588
[TBL] [Abstract][Full Text] [Related]
28.
Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
[TBL] [Abstract][Full Text] [Related]
29. Is 9-field IMRT superior to 7-field IMRT in the treatment of nasopharyngeal carcinoma?
Ibrahim MS; Attalla EM; El Naggar M; Elshemey WM
Indian J Cancer; 2020; 57(4):388-392. PubMed ID: 33078744
[TBL] [Abstract][Full Text] [Related]
30. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.
Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W
J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes with whole-field versus split-field intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma.
Lin CS; Chen YW; Liu SC; Tsao CC; Lin KT; Lee SP; Fan CY; Liu MY; Shen PC; Jen YM
Head Neck; 2019 Mar; 41(3):598-605. PubMed ID: 30597692
[TBL] [Abstract][Full Text] [Related]
32. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
Luo Y; Qin Y; Lang J
Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
[TBL] [Abstract][Full Text] [Related]
33. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma.
Liu YP; Lv X; Zou X; Hua YJ; You R; Yang Q; Xia L; Guo SY; Hu W; Zhang MX; Chen SY; Lin M; Xie YL; Liu LZ; Sun R; Huang PY; Fan W; Guo X; Hong MH; Chen MY
Cancer Commun (Lond); 2019 Nov; 39(1):75. PubMed ID: 31730020
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
[TBL] [Abstract][Full Text] [Related]
35. Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy.
Huang TL; Tsai MH; Chuang HC; Chien CY; Lin YT; Tsai WL; Fang FM
Radiat Oncol; 2020 Apr; 15(1):84. PubMed ID: 32307024
[TBL] [Abstract][Full Text] [Related]
36. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.
Chen L; Zhang Y; Lai SZ; Li WF; Hu WH; Sun R; Liu LZ; Zhang F; Peng H; Du XJ; Lin AH; Sun Y; Ma J
Oncologist; 2019 Jan; 24(1):e38-e45. PubMed ID: 30082487
[TBL] [Abstract][Full Text] [Related]
37. Analysis of rare periparotid recurrence after parotid gland-sparing intensity-modulated radiotherapy for nasopharyngeal carcinoma.
Xu Y; Zhang M; Yue Q; Zong J; Lin J; Sun R; Qiu S; Lin S; Pan J
Cancer Radiother; 2016 Jul; 20(5):377-83. PubMed ID: 27372558
[TBL] [Abstract][Full Text] [Related]
38. The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement.
Tang LL; Tang XR; Li WF; Chen L; Tian L; Lin AH; Sun Y; Ma J
Oral Oncol; 2017 Jun; 69():68-73. PubMed ID: 28559023
[TBL] [Abstract][Full Text] [Related]
39. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.
Liu F; Xi XP; Wang H; Han YQ; Xiao F; Hu Y; He Q; Zhang L; Xiao Q; Liu L; Luo L; Li Y; Mo Y; Ma HZ
Radiat Oncol; 2017 Jan; 12(1):15. PubMed ID: 28587681
[TBL] [Abstract][Full Text] [Related]
40. Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China.
Huang J; Yang ZY; Wu B; Ding Q; Qin Y; Zhang ZJ; Yin ZY; Liang ZW; Han J; Wang Y; Peng ZJ; Peng G; Li Q; Wu G; Yang KY
Curr Med Sci; 2021 Aug; 41(4):737-745. PubMed ID: 34403099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
